Purchase this database of 90+ companies developing mRNA Therapeutics
Messenger RNA (mRNA) encodes the most fundamental building block of the cell: The protein. Despite this pivotal position in the cell, the role of mRNA as a therapeutic has so far been limited.
However, recently, mRNA-based vaccines have proved to be the most critical response to the global COVID-19 pandemic, and multiple mRNA vaccine companies are developing effective vaccines that have been distributed around the world. This new approach, with mRNA companies such as Moderna Therapeutics, BioNTech and CureVac in the forefront, has revealed a powerful new class of therapeutics, which is currently showing eminent potential within multiple disease areas. For instance, mRNA vaccines are expected to change the therapeutic landscape for multiple infectious diseases, with prophylactic vaccines having shown prophylactic effects against viral infections from influenza-A, RSV, zika virus and HIV.
Other approaches have been taken to develop therapeutics by mRNA companies for the treatment of genetic diseases, such as cystic fibrosis or glycogen storage diseases. In these diseases, either a non-functional protein is present or the protein is completely missing due to genetic mutations. Synthetic mRNA delivered to the cell functions to replace the missing protein with a functional variant.
Likewise, mRNA companies have shown that therapeutics based on mRNA have tremendous potential in multiple cancer types. This has led to the rise of personalized mRNA cancer vaccine companies, mRNA based CAR-T cell therapy companies, mRNA encoded antibody companies and intratumoral mRNA based cytokine treatment companies.
This database contains more than 70 confirmed mRNA companies with therapeutic assets under development, this being preclinical or clinical development.
You can read more about mRNA companies and the technology behind them in the blog post released by Stargazing Bio Research in relation to our mRNA company database here.